ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic Journal Article


Authors: Yahalom, J.; Dabaja, B. S.; Ricardi, U.; Ng, A.; Mikhaeel, N. G.; Vogelius, I. R.; Illidge, T.; Qi, S.; Wirth, A.; Specht, L.; on behalf of the International Lymphoma Radiation Oncology Group (ILROG)
Article Title: ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic
Abstract: The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using radiation therapy (RT) in hematological malignancies are widely used in many countries. The emergency situation created by the COVID-19 pandemic may result in limitations of treatment resources. Furthermore, in recognition of the need to also reduce the exposure of patients and staff to potential infection with COVID-19, the ILROG task force has made recommendations for alternative radiation treatment schemes. The emphasis is on maintaining clinical efficacy and safety by increasing the dose per fraction while reducing the number of daily treatments. The guidance is informed by adhering to acceptable radiobiological parameters and clinical tolerability. The options for delaying or omitting RT in some hematological categories are also discussed. © 2020 by The American Society of Hematology.
Journal Title: Blood
Volume: 135
Issue: 21
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2020-05-21
Start Page: 1829
End Page: 1832
Language: English
DOI: 10.1182/blood.2020006028
PUBMED: 32275740
PROVIDER: scopus
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Joachim Yahalom
    457 Yahalom